LUC00247I2 - - Google Patents

Download PDF

Info

Publication number
LUC00247I2
LUC00247I2 LU00247C LUC00247C LUC00247I2 LU C00247 I2 LUC00247 I2 LU C00247I2 LU 00247 C LU00247 C LU 00247C LU C00247 C LUC00247 C LU C00247C LU C00247 I2 LUC00247 I2 LU C00247I2
Authority
LU
Luxembourg
Application number
LU00247C
Other languages
French (fr)
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00247(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of LUC00247I2 publication Critical patent/LUC00247I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)
LU00247C 2005-06-27 2021-12-29 LUC00247I2 (h)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition

Publications (1)

Publication Number Publication Date
LUC00247I2 true LUC00247I2 (h) 2024-10-04

Family

ID=36716943

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92085C LU92085I2 (fr) 2005-06-27 2012-10-19 Neisseria meningitidis groupe A polysaccharides conjugés à une protéine porteuse en utilisant la chimie de condensation carbodiimide
LU00247C LUC00247I2 (h) 2005-06-27 2021-12-29

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92085C LU92085I2 (fr) 2005-06-27 2012-10-19 Neisseria meningitidis groupe A polysaccharides conjugés à une protéine porteuse en utilisant la chimie de condensation carbodiimide

Country Status (36)

Country Link
US (13) US8398983B2 (h)
EP (11) EP1896061B1 (h)
JP (9) JP5037503B2 (h)
KR (7) KR101351873B1 (h)
CN (3) CN102218138A (h)
AP (1) AP2436A (h)
AR (3) AR056397A1 (h)
AT (3) ATE462444T1 (h)
AU (7) AU2006263936B2 (h)
BE (1) BE2012C042I2 (h)
BR (5) BRPI0612655B1 (h)
CA (5) CA2611964C (h)
CY (5) CY1109996T1 (h)
DE (1) DE602006013313D1 (h)
DK (7) DK1896065T4 (h)
EA (4) EA012506B1 (h)
ES (9) ES2898451T3 (h)
FR (1) FR22C1008I2 (h)
HR (4) HRP20120102T1 (h)
HU (7) HUE046905T2 (h)
IL (8) IL187924A (h)
LT (1) LT2351578T (h)
LU (2) LU92085I2 (h)
MA (4) MA29603B1 (h)
MX (5) MX2007016402A (h)
MY (3) MY147490A (h)
NL (1) NL300549I2 (h)
NO (4) NO345422B1 (h)
NZ (6) NZ590204A (h)
PE (6) PE20070123A1 (h)
PL (8) PL1896062T3 (h)
PT (8) PT1896063E (h)
SI (8) SI1896063T1 (h)
TW (5) TWI422386B (h)
UA (2) UA95238C2 (h)
WO (6) WO2007000342A2 (h)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228384B1 (en) * 2000-06-29 2013-03-28 Glaxosmithkline Biolog Sa Vaccine compositions
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
PT2191844E (pt) 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2006263936B2 (en) * 2005-06-27 2010-05-20 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
ES2443529T3 (es) 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Vacunación múltiple incluyendo meningococo del serogrupo C
UA96583C2 (uk) 2005-12-22 2011-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Вакцина, що містить кон'югати капсулярного полісахариду streptococcus pneumoniae
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
DK2004225T3 (da) * 2006-03-22 2012-08-06 Novartis Ag Programmer for vaccination med meningocockonjugater
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
AU2008267208B2 (en) * 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag Formulações de vacinas meningocócicas
WO2010023216A1 (en) * 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccine
US11065323B2 (en) 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
SI2510947T1 (sl) 2009-04-14 2016-05-31 Glaxosmithkline Biologicals S.A. Sestavki za imunizacijo proti Staphylococcus aureus
KR101450958B1 (ko) * 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
DK2459216T3 (da) 2009-09-02 2013-12-09 Novartis Ag Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
BR112012008338A2 (pt) 2009-09-10 2019-09-24 Novartis Ag combinação de vacinas contra doenças do trato respiratório.
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
US9315530B2 (en) 2010-09-01 2016-04-19 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
BR112014016223A8 (pt) 2011-12-29 2017-07-04 Novartis Ag combinações adjuvantes de proteínas de ligação de fator h meningocócico
CN104302315B (zh) * 2012-01-30 2018-02-06 印度血清研究所私人有限公司 免疫原性组合物及其制备方法
CN104114706A (zh) 2012-02-02 2014-10-22 诺华股份有限公司 用于脑膜炎球菌中增加的蛋白表达的启动子
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
ITMI20121597A1 (it) * 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
KR20150100665A (ko) 2012-11-30 2015-09-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 슈도모나스 항원 및 항원 조합
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014095771A1 (en) 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
CA2899787A1 (en) 2013-02-01 2014-08-07 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor agonists
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2903322C (en) * 2013-03-18 2023-09-05 Glaxosmithkline Biologicals S.A. A method of immunising against neisseria meningitidis infection
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
IN2014DE02450A (h) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
AU2015208821B2 (en) * 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
EP3131576B1 (en) * 2014-04-17 2021-06-30 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PE20240927A1 (es) * 2015-07-21 2024-04-30 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
MY199399A (en) * 2016-03-15 2023-10-25 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Novel polysaccharide-protein conjugates and process to obtain thereof
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
AU2017321863B2 (en) * 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
US11027005B2 (en) * 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MA47223A (fr) 2016-12-30 2019-11-06 Sutrovax Inc Conjugués polypeptide-antigène avec des acides aminés non naturels
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
JP7218358B2 (ja) 2017-09-07 2023-02-06 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
BR112023009109A2 (pt) 2020-11-13 2024-02-06 Glaxosmithkline Biologicals Sa Carreadores de proteína bacteriana e métodos de conjugação
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
WO2025021704A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (en) * 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
HU193083B (en) * 1984-02-22 1987-08-28 Sandoz Ag Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) * 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
EP0417177B1 (de) 1988-05-31 1993-10-27 Beatrice KÖNIG-HAUG Regalsystem
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
CA2063271A1 (en) 1989-07-14 1991-01-15 Subramonia Pillai Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
BR9007917A (pt) 1989-12-14 1992-10-20 Ca Nat Research Council Vacina aperfeicoada de conjugado polissacaridico meningogocico
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
EP1958646A1 (en) 1992-02-11 2008-08-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993021769A1 (en) * 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
DE122010000016I1 (de) 1992-05-23 2010-07-08 Glaxosmithkline Biolog Sa Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69323264D1 (de) 1992-10-27 1999-03-11 American Cyanamid Co Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
WO1994014086A1 (en) 1992-12-14 1994-06-23 Western Atlas International, Inc. Removable piston bore liner for hydraulically actuated seismic vibrator
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
EP0833662B2 (en) 1995-06-23 2011-01-26 SmithKline Beecham Biologicals S.A. A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
DE69709690T2 (de) 1996-10-23 2002-09-12 Matsushita Electric Industrial Co., Ltd. Optische Platte
ES2277362T5 (es) 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Antígenos y vacunas de streptococcus pneumoniae
WO1998026799A1 (en) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2303105A1 (en) 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
EP1109576B1 (en) * 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
WO2000033882A1 (en) † 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
ATE422899T1 (de) 1998-12-21 2009-03-15 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
ES2242604T3 (es) 1999-02-26 2005-11-16 Chiron Corporation Microemulsiones con macroparticulas y microparticulas adsorbidas.
PT1163000E (pt) * 1999-03-19 2008-03-20 Glaxosmithkline Biolog Sa Vacina contra antigénios de bactérias
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
EP1192242B1 (en) 1999-06-25 2010-05-05 Wyeth Holdings Corporation Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
CA2393298C (en) 1999-12-02 2011-02-01 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
HU228384B1 (en) * 2000-06-29 2013-03-28 Glaxosmithkline Biolog Sa Vaccine compositions
CA2416137C (en) * 2000-07-27 2013-01-29 Dan Granoff Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
MX357775B (es) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
PL226184B1 (pl) 2001-01-23 2017-06-30 Aventis Pasteur Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
KR100981471B1 (ko) 2002-03-15 2010-09-10 더 큐레이터스 오브 더 유니버시티 오브 미주리 효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의ｐ4 변형 단백질
ATE419278T1 (de) * 2002-03-26 2009-01-15 Novartis Vaccines & Diagnostic Modifizierte saccharide mit verbesserter stabilität in wasser
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
NZ536859A (en) 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
NZ574530A (en) * 2002-08-02 2010-12-24 Glaxosmithkline Biolog Sa Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB-neisseria minigitidis
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2775098T3 (es) 2002-10-11 2020-07-23 Glaxosmithkline Biologicals Sa Vacunas de polipéptidos para protección amplia contra linajes meningocócicos hipervirulentos
CN1401328A (zh) * 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
DK2395073T3 (en) * 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
PT2191844E (pt) * 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
DK1601689T3 (da) 2003-03-13 2008-03-25 Glaxosmithkline Biolog Sa Oprensningsfremgangsmåde for bakterielt cytolysin
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
BRPI0410341B8 (pt) * 2003-05-07 2021-05-25 Sanofi Pasteur Inc conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2530434A1 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
CN1863553B (zh) * 2003-08-06 2011-05-04 美国政府健康及人类服务部 多糖-蛋白轭合物疫苗
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US6995363B2 (en) * 2003-08-21 2006-02-07 Applera Corporation Reduction of matrix interference for MALDI mass spectrometry analysis
WO2005032584A2 (en) * 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
CA2550927A1 (en) * 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
RU2347586C2 (ru) * 2004-04-05 2009-02-27 Пфайзер Продактс Инк. Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции
US9402915B2 (en) * 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
BRPI0515520A (pt) * 2004-09-22 2008-07-29 Glaxosmithkline Biolog Sa composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP2351772B1 (en) * 2005-02-18 2016-07-13 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
DK1868645T3 (da) * 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
PL1885734T3 (pl) * 2005-05-06 2015-08-31 Novartis Ag Immunogeny dla szczepionek przeciwko Meningitidis-A
AU2006263936B2 (en) * 2005-06-27 2010-05-20 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
ES2443529T3 (es) * 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Vacunación múltiple incluyendo meningococo del serogrupo C
ES2353516T3 (es) * 2005-09-05 2011-03-02 Glaxosmithkline Biologicals S.A. Ensayo bactericida del suero para antisueros específicos de n. meningitidis.
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
UA96583C2 (uk) * 2005-12-22 2011-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Вакцина, що містить кон'югати капсулярного полісахариду streptococcus pneumoniae
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0620418A2 (pt) * 2005-12-23 2011-11-08 Glaxosmithkline Biolog Sa método para imunizar um paciente humano contra uma doença, usos de pelo menos dois e de pelo menos sete, dez, onze, treze ou quatorze conjugados e das vacinas, e, kit
KR101838938B1 (ko) * 2006-03-17 2018-03-15 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
BRPI0710210A2 (pt) * 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
CA2656474A1 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
KR20090060410A (ko) 2006-07-21 2009-06-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 인간 내인성 레트로바이러스 폴리펩타이드 조성물 및 이들의 사용 방법
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008111374A1 (ja) * 2007-03-14 2008-09-18 Konica Minolta Business Technologies, Inc. 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
CL2008001258A1 (es) 2007-05-02 2009-01-16 Glaxosmithkline Biologicals Sa Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
CN101678094B (zh) 2007-06-04 2014-08-27 诺华股份有限公司 脑膜炎疫苗制剂
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2010023216A1 (en) 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccine
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
WO2011138636A1 (en) * 2009-09-30 2011-11-10 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN103124737A (zh) * 2010-03-11 2013-05-29 葛兰素史密丝克莱恩生物有限公司 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗
WO2011155196A1 (ja) * 2010-06-11 2011-12-15 パナソニック株式会社 語音聴取の評価システム、その方法およびそのプログラム
JP6170932B2 (ja) * 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
CN104302315B (zh) * 2012-01-30 2018-02-06 印度血清研究所私人有限公司 免疫原性组合物及其制备方法
EP2852414B9 (en) * 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
HUE061273T2 (hu) * 2012-12-05 2023-06-28 Glaxosmithkline Biologicals Sa Immunogén készítmény
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
BR112017002183A2 (pt) * 2014-08-05 2018-01-16 Glaxosmithkline Biologicals S.A. conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
AU2017321863B2 (en) * 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN118021947A (zh) * 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
US11179453B2 (en) * 2017-07-18 2021-11-23 Serum Institute Of India Pvt Ltd Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof

Also Published As

Publication number Publication date
HRP20170457T1 (hr) 2017-05-19
IL188072A0 (en) 2008-03-20
EP1896064A2 (en) 2008-03-12
PT1896061T (pt) 2019-08-01
HUE046905T2 (hu) 2020-03-30
PT1896065E (pt) 2011-08-31
WO2007000342A2 (en) 2007-01-04
AU2010203115A1 (en) 2010-08-12
MA29603B1 (fr) 2008-07-01
HUE056842T2 (hu) 2022-03-28
CA2612963C (en) 2016-10-18
PL1896063T3 (pl) 2012-04-30
AU2006263965A1 (en) 2007-01-04
JP2013107913A (ja) 2013-06-06
TW200738259A (en) 2007-10-16
JP2008543904A (ja) 2008-12-04
ATE516816T1 (de) 2011-08-15
AU2006263963A1 (en) 2007-01-04
UA95238C2 (uk) 2011-07-25
NZ564607A (en) 2011-06-30
EP1896066B8 (en) 2022-01-19
BRPI0612656A2 (pt) 2010-11-30
DK2878307T3 (da) 2019-10-07
LT2351578T (lt) 2017-04-10
US20190298822A1 (en) 2019-10-03
CY2012027I1 (el) 2015-10-07
PL1896062T3 (pl) 2010-08-31
ES2377075T5 (es) 2016-04-29
CA2611960C (en) 2015-05-05
IL213718A0 (en) 2011-07-31
US8846049B2 (en) 2014-09-30
HUE045482T2 (hu) 2019-12-30
NO345422B1 (no) 2021-01-25
JP2008543909A (ja) 2008-12-04
US20090252759A1 (en) 2009-10-08
KR101359953B1 (ko) 2014-02-21
BRPI0612669B8 (pt) 2021-05-25
US8883163B2 (en) 2014-11-11
AU2006263936B2 (en) 2010-05-20
US9931397B2 (en) 2018-04-03
US20080193476A1 (en) 2008-08-14
TW201336507A (zh) 2013-09-16
EA200702576A1 (ru) 2008-06-30
WO2007000327A1 (en) 2007-01-04
ES2750243T3 (es) 2020-03-25
EP1896061B1 (en) 2019-06-12
US20200000911A1 (en) 2020-01-02
CA2611964C (en) 2016-11-08
IL222346A (en) 2015-07-30
EP2351578A1 (en) 2011-08-03
BRPI0612656B1 (pt) 2021-09-08
BRPI0612669B1 (pt) 2019-08-13
CA2612980C (en) 2019-01-15
MX2007016405A (es) 2008-03-07
EP3009146A1 (en) 2016-04-20
MY148110A (en) 2013-02-28
PT3009146T (pt) 2021-11-30
WO2007000343A3 (en) 2007-05-31
WO2007000341A2 (en) 2007-01-04
AP2436A (en) 2012-08-31
AU2006263944A1 (en) 2007-01-04
ATE462444T1 (de) 2010-04-15
AR053935A1 (es) 2007-05-23
BRPI0612655A2 (pt) 2010-11-30
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
BRPI0612654B8 (pt) 2021-05-25
EP1896062B1 (en) 2010-03-31
NZ564370A (en) 2011-10-28
EA012214B1 (ru) 2009-08-28
IL188045A0 (en) 2008-03-20
SI1896065T2 (sl) 2014-12-31
AU2010203115B2 (en) 2012-03-15
CY1112698T1 (el) 2016-02-10
EP3009146B1 (en) 2021-10-20
KR20080030577A (ko) 2008-04-04
AU2006263944B2 (en) 2012-03-01
ES2340711T3 (es) 2010-06-08
KR101408113B1 (ko) 2014-06-16
DK1896063T3 (da) 2012-03-19
CN102526723A (zh) 2012-07-04
US8431136B2 (en) 2013-04-30
JP2008543907A (ja) 2008-12-04
TWI537001B (zh) 2016-06-11
IL213718A (en) 2013-07-31
MY147490A (en) 2012-12-14
BRPI0612670B1 (pt) 2020-04-28
KR101321056B1 (ko) 2013-10-30
AU2010212417A1 (en) 2010-09-09
TWI422386B (zh) 2014-01-11
DK1896061T3 (da) 2019-08-26
HUE031380T2 (en) 2017-07-28
BRPI0612656A8 (pt) 2018-01-23
ES2662651T3 (es) 2018-04-09
HRP20100211T1 (hr) 2010-05-31
PT2878307T (pt) 2019-10-24
US20080199490A1 (en) 2008-08-21
JP5297800B2 (ja) 2013-09-25
WO2007000314A3 (en) 2007-05-31
SI1896062T1 (sl) 2010-07-30
JP2008543908A (ja) 2008-12-04
US20150044253A1 (en) 2015-02-12
EP2283857B1 (en) 2019-07-24
DK1896065T3 (da) 2011-08-29
TWI477283B (zh) 2015-03-21
KR101532068B1 (ko) 2015-06-29
PL1896065T3 (pl) 2011-12-30
EP2201961B1 (en) 2018-01-24
IL187924A0 (en) 2008-03-20
NO342815B1 (no) 2018-08-13
AU2006263963B2 (en) 2010-05-13
JP5037503B2 (ja) 2012-09-26
HUE047211T2 (hu) 2020-04-28
BRPI0612655A8 (pt) 2018-01-30
WO2007000342A8 (en) 2008-07-10
US20180064806A1 (en) 2018-03-08
BE2012C042I2 (h) 2021-07-19
AU2006263964B2 (en) 2010-05-20
EP2878307B1 (en) 2019-07-24
AU2010203115C1 (en) 2013-05-02
HUS1200023I1 (hu) 2021-03-29
EP1896066B1 (en) 2021-10-27
EA200702574A1 (ru) 2008-06-30
BRPI0612654A2 (pt) 2012-10-02
CA2611964A1 (en) 2007-01-04
WO2007000343A2 (en) 2007-01-04
CN103083657A (zh) 2013-05-08
JP5731737B2 (ja) 2015-06-10
NZ564605A (en) 2011-01-28
ES2898451T3 (es) 2022-03-07
US20130004532A1 (en) 2013-01-03
PL2351578T3 (pl) 2017-07-31
PE20142165A1 (es) 2015-01-09
US20170065714A1 (en) 2017-03-09
JP2008543905A (ja) 2008-12-04
IL213795A (en) 2013-05-30
MX2007016403A (es) 2008-03-07
CN102526723B (zh) 2017-07-07
IL188072A (en) 2017-07-31
ES2747025T3 (es) 2020-03-09
PT1896063E (pt) 2012-02-13
NO20076363L (no) 2008-03-26
DK1896065T4 (da) 2014-10-20
NL300549I2 (h) 2017-01-03
EP1896065A2 (en) 2008-03-12
PT2283857T (pt) 2019-10-24
HK1116414A1 (en) 2008-12-24
TW201414490A (zh) 2014-04-16
DK2283857T3 (da) 2019-10-28
MX2007016402A (es) 2008-03-07
ES2377075T3 (es) 2012-03-22
EA012528B1 (ru) 2009-10-30
WO2007000342A3 (en) 2007-05-31
FR22C1008I1 (fr) 2022-04-29
CY1109996T1 (el) 2014-09-10
JP2013209395A (ja) 2013-10-10
LU92085I9 (h) 2019-01-04
EP1896062A1 (en) 2008-03-12
PE20110096A1 (es) 2011-03-07
US20090041802A1 (en) 2009-02-12
KR20130086087A (ko) 2013-07-30
EP1896065B2 (en) 2014-09-03
SI2351578T1 (sl) 2017-05-31
EP1896063A1 (en) 2008-03-12
ES2901378T3 (es) 2022-03-22
CA2612980A1 (en) 2007-01-04
HK1114011A1 (en) 2008-10-24
ES2741529T3 (es) 2020-02-11
NZ564371A (en) 2010-05-28
HK1116413A1 (en) 2008-12-24
HUS2200002I1 (hu) 2022-12-28
PE20070163A1 (es) 2007-03-01
FR22C1008I2 (fr) 2024-01-19
MA29993B1 (fr) 2008-12-01
AR056397A1 (es) 2007-10-10
US8398983B2 (en) 2013-03-19
UA95237C2 (uk) 2011-07-25
LU92085I2 (fr) 2012-12-19
SI2878307T1 (sl) 2019-11-29
JP5718960B2 (ja) 2015-05-13
HRP20110567T4 (xx) 2015-01-16
EP2201961A1 (en) 2010-06-30
PE20110072A1 (es) 2011-02-04
US20130171188A1 (en) 2013-07-04
MX2007016236A (es) 2008-03-07
NO20076350L (no) 2008-03-26
HK1206587A1 (en) 2016-01-15
AU2006263964A1 (en) 2007-01-04
CY2012027I2 (el) 2015-10-07
JP2013018798A (ja) 2013-01-31
IL188046A0 (en) 2008-03-20
JP5965512B2 (ja) 2016-08-03
EA013374B1 (ru) 2010-04-30
CN103083657B (zh) 2016-06-08
NO345305B1 (no) 2020-12-07
ES2621780T3 (es) 2017-07-05
IL214657A0 (en) 2011-09-27
HRP20110567T1 (en) 2011-09-30
KR101351870B1 (ko) 2014-02-17
AP2007004274A0 (en) 2007-12-31
ATE536884T1 (de) 2011-12-15
KR20080018226A (ko) 2008-02-27
MY147783A (en) 2013-01-31
PE20070499A1 (es) 2007-05-21
SI1896065T1 (sl) 2011-10-28
EP1896063B1 (en) 2011-12-14
HUS000497I2 (hu) 2021-03-29
SI1896063T1 (sl) 2012-03-30
SI1896061T1 (sl) 2019-10-30
US11241495B2 (en) 2022-02-08
KR20080025184A (ko) 2008-03-19
US9789179B2 (en) 2017-10-17
US20100215686A1 (en) 2010-08-26
EA200702575A1 (ru) 2008-06-30
EP1896061A2 (en) 2008-03-12
BRPI0612654B1 (pt) 2021-05-04
NO20076343L (no) 2008-03-25
CY1111827T1 (el) 2015-10-07
NZ564606A (en) 2010-10-29
EP1896065B1 (en) 2011-07-20
EP2351578B1 (en) 2017-01-18
SI2283857T1 (sl) 2019-11-29
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
TW200730187A (en) 2007-08-16
PT1896062E (pt) 2010-05-17
EA012506B1 (ru) 2009-10-30
JP5280199B2 (ja) 2013-09-04
KR20130122810A (ko) 2013-11-08
BRPI0612670A2 (pt) 2010-11-30
PL1896061T3 (pl) 2020-02-28
US9358279B2 (en) 2016-06-07
WO2007000341A3 (en) 2007-05-31
IL188046A (en) 2012-03-29
CN102218138A (zh) 2011-10-19
US10166287B2 (en) 2019-01-01
PE20070123A1 (es) 2007-02-08
MA29569B1 (fr) 2008-06-02
CA2612957A1 (en) 2007-01-04
US9486515B2 (en) 2016-11-08
NO344452B1 (no) 2019-12-09
JP5769688B2 (ja) 2015-08-26
DK2351578T3 (en) 2017-04-24
NZ590204A (en) 2012-02-24
WO2007000314A2 (en) 2007-01-04
IL187924A (en) 2011-11-30
IL213795A0 (en) 2011-07-31
CY1118646T1 (el) 2017-07-12
US20090136541A1 (en) 2009-05-28
KR20080024222A (ko) 2008-03-17
JP2015134829A (ja) 2015-07-27
MX2007016237A (es) 2008-03-07
CA2611960A1 (en) 2007-01-04
US8329184B2 (en) 2012-12-11
PL2283857T3 (pl) 2020-02-28
PL3009146T3 (pl) 2022-02-07
EA200702577A1 (ru) 2008-06-30
WO2007000322A1 (en) 2007-01-04
CA2612957C (en) 2016-07-19
EP2283857A1 (en) 2011-02-16
BRPI0612670B8 (pt) 2021-05-25
EP2878307A1 (en) 2015-06-03
EP1896066A2 (en) 2008-03-12
KR101351873B1 (ko) 2014-02-17
PL1896065T5 (pl) 2014-12-31
MA29602B1 (fr) 2008-07-01
BRPI0612669A2 (pt) 2010-11-30
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
DK1896062T3 (da) 2010-06-28
EP1896063B2 (en) 2016-03-02
CA2612963A1 (en) 2007-01-04
AR056396A1 (es) 2007-10-10
SI3009146T1 (sl) 2022-02-28
AU2006263936A1 (en) 2007-01-04
DE602006013313D1 (de) 2010-05-12
TWI407970B (zh) 2013-09-11
HRP20120102T1 (hr) 2012-02-29
US10245317B2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
BE2012C042I2 (h)
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico
BRPI0601402B8 (pt) Aplicador de grampos cirúrgicos
BR122017004707A2 (h)
BRPI0609157A8 (h)
BRPI0608519A2 (h)
BR122020005056A2 (h)
AP2140A (h)
BR122016029989A2 (h)
BRPI0604219A (h)
BRPI0618215B8 (h)
BY2237U (h)
CN105122969C (h)
CN300726000S (zh) 鞋帮
CN300726016S (zh) 鞋帮
CN300734568S (zh) 长沙发椅
CN300726699S (zh) 调料瓶套装(d)
CN300726698S (zh) 调料瓶套装(e)
CN300725990S (zh) 鞋帮
CN300725991S (zh) 鞋帮
CN300725992S (zh) 鞋底
CN300725993S (zh) 鞋帮
CN300725994S (zh) 鞋底
CN300725995S (zh) 鞋帮
CN300725996S (zh) 鞋帮